Mauna Kea Technologies manufactures Cellvizio Lab, confocal probe based imaging system, providing cellular-level images with minimal invasiveness for longitudinal studies.
Discover
Related topics
Advances in Leukemia research using shear flow and Bioflux system
Feb 3, 2023
Leukemia is a rare cancer with many subtypes. The production of abnormal leukocytes create disruptions in the immune...
Webinar: Dose Reduction and Image Enhancement in Preclinical Mouse Imaging using Deep Learning
Jan 31, 2023
In this webinar, ir. Florence Muller (Ghent University - University of Pennsylvania) is presenting two recent studies...
Advance your Spatial Biology, customize your panel design with RareCyte Orion reagents
Jan 23, 2023
Orion system, the highly multiplexed fluorescent imaging system, in combination with dedicated reagents, empower...
Extensive assessment of Cytokine production on the NovoCyte Advanteon flow cytometer
Jan 13, 2023
Cytokines are small molecules essential for immune cell response to activation by pathogens, autoimmunity, or...
New installation of Cytek Aurora in Slovenia
Jan 11, 2023
2nd spectral flowcytometer Aurora from Cytek was installed at National Institute of Biology in Slovenia
Microfluidic cell sorter sample preparation for genomic assays
Dec 16, 2022
Single-cell RNA-Sequencing has led to many novel discoveries such as the detection of rare cell populations, microbial...
Dec 1, 2022
Cytek Cloud is the new digital ecosystem that supports full spectrum flow cytometry research from panel design to data...
See More, Sort More with Cytek Full Spectrum Systems
Nov 28, 2022
Still wondering whether to join the shift to full spectrum cytometry? Easily transfer assays from your Cytek Northern...
Demonstrate the value of RareCyte Orion system via web-based Minerva viewer
Nov 25, 2022
The HTA CRC Atlas X dataset contains images and other data being used for construction of an atlas of human colorectal...
Practical aspects of an imaging study: live in vivo scanning
Nov 11, 2022
In this webinar, MOLECUBES will present a live in vivo demonstration, showing the entire workflow from animal...
Nov 23, 2017
Nonalcoholic fatty liver disease (NAFLD) directly affects 10–30% of the human population and is characterized by pathological alterations ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, and irreversible cirrhosis. NAFLD is considered a hepatic component of metabolic syndromes and is thus strongly associated with metabolic diseases such as obesity, insulin resistance, hypertension, and dyslipidemia. The prevalence of NAFLD is strongly associated with obesity and the metabolic complications of over-nutrition, which usually accompany visceral obesity. Visceral obesity is particularly associated with NAFLD. The amount of visceral fat is directly linked to the severity of liver inflammation and fibrosis in NAFLD. Human and animal studies indicate that NAFLD is strongly associated with VAT inflammation and elevated circulating inflammatory factors such as inflammatory adipokines and lipids. It is reasonable that targeting visceral adipose tissue (VAT) can contribute to the treatment and prevention of NAFLD. Accordingly, we thought it plausible that the anti-angiogenic-induced VAT loss may attenuate NAFLD during obesity.
Visualization of real-time visceral adipose tissue vasculature was performed using an FCFM imaging system (Cellvizio, Mauna Kea Technologies) with excitation and emission wavelengths of 488 and 520 nm, respectively.
Brand profile
Mauna Kea Technologies manufactures Cellvizio Lab, confocal probe based imaging system, providing cellular-level images with minimal invasiveness for longitudinal studies.
More info at:
www.cellviziolab.com/